We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Showcases Latest Hematology and Hemostasis Solutions at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022

Horiba Medical (Kyoto, Japan) showcased its hematology and hemostasis solutions at the EUROMEDLAB 2022 which took place from April 10 to 14 at the ICM Internationales Congress Center, Munich, Germany. More...

The company also presented scientific posters on its high range hematology solutions during the poster session time.

At its exhibition booth, Horiba showcased its automation high-end HELO Global Hematology Solution covering all the needs of a high throughput automated hematology platform. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses all the needs of laboratories, but helps to optimize their TAT, floor space and reagent storage. Among its Yumizen range of hematology solutions, Horiba displayed its Yumizen H2500/H1500 and the Yumizen H550 hematology analyzers. The Yumizen H2500/H1500 has a real throughput of 120 samples per hour for CBC-DIFF NRBC and slides and come with on board reagents (5 for Yumizen H2500 and 4 for Yumizen H1500). Along with testing for up to 55 parameters, their automatic 360°C rotative sample mixing provides perfect homogeneity. On the other hand, the Yumizen H550 is a compact 6-diff hematology analyzer with an auto sampling system which aims at providing a full walk away capability to a variety of clinical environments: hospitals, satellite labs, emergency care, small independent labs, and doctors’ offices.

Among its Yumizen range of hemostasis solutions, Horiba displayed its Yumizen G1550/G1500 and Yumizen G400 hemostasis analyzers. The Yumizen G1550/G1500 automated analyzer offers routine and specialized testing in a single analysis system along with liquid and ready-to-use reagents for 80% of laboratory activity. It offers up to eight measuring channels with two wavelength combinations, continuous loading, and simplified anteriority management thanks to a large database of 1,000,000 results. The Yumizen G400 semi-automated hemostasis analyzer offers four independent measuring channels and 20 incubation positions and is easy to operate with an innovative user interface. Other solutions on display at the Horiba EUROMEDLAB 2022 exhibition booth included the Yumizen SPS slide maker, the CellaVision DC-1 digital cell morphology system, the Yumizen P8000 middleware and expert validation station and the Yumizen T6000 automated conveyor.

Related Links:
Horiba Medical 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Urine Analyzer
respons® UDS100
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.